Clinical Trial Update: A Phase 2 Study Using Aliya PEF Plus Pembro for Sarcoma [Phase 2]

View source ↗

Summary

Phase 2 study of Aliya PEF Plus pembrolizumab for soft tissue sarcoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Soft Tissue Sarcoma

Drugs mentioned

• Aliya PEF Plus
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Sarcoma Oncology Research Center, LLC | Conditions: Soft Tissue Sarcoma | Phase 2 | Status: WITHDRAWN